Serum Institute of India to restart the production of covid vaccines (COVISHIELD). At present, they have an inventory of 6 million doses of Covovax. Adar Poonawalla, Chief Executive Officer of SII said that they are planning to restart the production after a year. They are planning more supply of doses to hospitals. Batch by batch they are planning to make about 5-6 million doses. They say people are likely to take Covishield as a third dose. SII’s Covovax (Novavax vaccine supplied to US) got the regulator’s assurance as a heterologous booster few days ago.
SII are also into new experiment on human blood samples for neutralizing antibodies against Omicron and XXB variant of Omicron. Private hospitals have more demand for these vaccines. After the first and second doses of vaccine everyone is into booster dose. Presently slumped in US and Europe. They also quoted that government has already done with first and second doses and now they are into booster dose, which has been done for half of the population, so they don’t expect government to buy more. SII is mainly focusing of private hospitals.
SII has also launched vaccine against cervical cancer to begin from June. It will cost about Rs. 300 and Rs 350 in private hospitals. It is named as Cervavac. The imported version of Cervavac can increase from Rs 3500 to 4000 per dose. The vaccine is concentrated and offered to girls of 9-14 age groups. The first dose will be offered to primary school students. The aim is to protect girls against cervical cancer caused by human papillomavirus.
No comments:
Post a Comment